Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person Mitochondrial amidoxime-reducing components 1 and 2 (MARC1 a...
| Class:Id | Summation:8936502 |
|---|---|
| _displayName | Mitochondrial amidoxime-reducing components 1 and 2 (MARC1 a... |
| _timestamp | 2016-10-25 10:24:16 |
| created | [InstanceEdit:8936503] Jassal, Bijay, 2016-08-22 |
| modified | [InstanceEdit:8943400] Jassal, Bijay, 2016-10-25 |
| text | Mitochondrial amidoxime-reducing components 1 and 2 (MARC1 and 2) are Mo-molybdopterin (Mo-MPT) cofactor-dependent, outer mitochondrial membrane-associated enzymes capable of reducing N-hydroxylated prodrugs and N-hydroxy-L-arginine (NOHA) and N-hydroxy-N-methyl-L-arginine (NHAM) into L-arginine and N(delta)-methyl-L-arginine, respectively. They are components of an N-hydroxylated prodrug-converting complex, also containing cytochrome b5 (CYB5B) and NADH cytochrome b5 reductase 3 (CYB5R3) (Jakobs et al. 2014, Gruenewald et al. 2008, Ott et al. 2014, 2015). The reduction of NOHA is described in this reaction. |
| (summation) | [Reaction:8936442] MARC1,MARC2 reduce N-hydroxylated compounds [Homo sapiens] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by Mitochondrial amidoxime-reducing components 1 and 2 (MARC1 a... (8936502)
